TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07083739: Phase II Clinical Trial on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 320 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,555,000

Rescue Site Savings

+$4,312,500

Unlock Full NCT07083739 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07083739 Rescue Dossier →